NANOVIRICIDES Schweinegrippewert - 500 Beiträge pro Seite

[tradepunk]

Mon, Apr 27, 2009
07:08 AM

NanoViricides, Inc. Says Flu-Cide Drug Designed to Destroy All Influenza A Viruses Including Swine and Bird Flu

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced that it is developing FluCide(â¢), its flagship anti-influenza drug candidate, to work against all influenza types and subtypes. FluCide has been shown to be effective against both common influenza subtype H1N1, as well as two different variants of bird flu subtype H5N1.

The Company has previously announced excellent results in both animal studies and cell culture studies against widely different influenza subtypes and strains. If these results are confirmed in further animal and human studies, then FluCide would likely be considered the best ever drug effective against all influenzas. The Company is communicating its capabilities to various agencies involved in the current epidemic response.

The current swine flu outbreak is significant in that the H1N1 virus causing it is novel (http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/ne… The US Department of Homeland Security has declared a Swine Flu Emergency yesterday. The WHO has said that the outbreak is an emergency of international concern (http://www.upi.com/Health_News/2009/04/26/DHS-declares-swine… The pig is known to be a transitional species for influenza viruses. That means re-assortment (i.e. mixing) of genes from bird flu, human flu, and swine flu viruses can take place in pigs. This can lead to more lethal, drug resistant novel strains to emerge from different existing ones.

"Nanoviricides(â¢) have clear advantages over antibodies and vaccines as antiviral strategies," said Dr. Diwan, President of NanoViricides. Antibodies are relatively specific to a particular virus strain or subtype. It is well known that HIV and influenza viruses among many others, quickly escape antibodies. Vaccines depend upon the development of antibodies by the host, and thus, cannot protect efficiently against those viruses which are continually changing their character, such as the influenza virus. Influenza vaccines in particular have to be developed with the strain that is expected to infect in the next yearâs cycle. It is well known that this is not a failure-proof strategy for epidemic-causing strains that are novel.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide⢠class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are âforward-looking statementsâ within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.




NanoViricides, Inc.
Amanda Schuon, 310-550-7200

[tradepunk]

Kürzel in D: NV3
in US: NNVC

[tradepunk]

[printguru]

CBMX würde ich auch beachten....

[1upandaway]

hier ist einiges in der pipeline,
http://www.nanoviricides.com/pipeline.html

ami board
http://investorshub.advfn.com/boards/board.aspx?board_id=410…

allans blog - hat das ding bei 10 cent empfohlen vor jahren
http://allallan.blogspot.com/2008/04/nnvc-valuation.html

chart längerfristig
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=nnvc

kam am freitag abend
http://www.ludlowcapital.com/reports/bio/nnvc.html

[1upandaway]

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide⢠class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

[tradepunk]

Antwort auf Beitrag Nr.: 37.048.485 von printguru am 27.04.09 18:18:43

Ja, aber da schreckt der optisch hohe Kurs ab. Prozentual dürften "die anderen" interessanter sein.

[1upandaway]

Ludlow Capital Group today posted an 18 1/2 minute interview with NanoViricides CEO Eugene Seymour that was conducted by telephone two days ago on the 25th.
http://investorshub.advfn.com/boards/read_msg.aspx?message_i…

[1upandaway]

Wednesday, April 29, 2009
Why aren’t new therapies for treating swine flu (and other diseases?) available?
http://nanochemreport.blogspot.com/2009/04/why-arent-new-the…

[Larry_1]

bin jetzt schon richtig fett im Minus
Frage: halten oder raushauen ?
Hat jemand eine Meinung ?

[1upandaway]

Antwort auf Beitrag Nr.: 37.081.124 von Larry_1 am 01.05.09 21:50:04

liegen lassen - 2-3 dollar dieses jahr müssten drinnen sein
müssten einige testergebnisse kommen die nächsten wochen/monate
mein ziel 100 usd die nächsten 5 jahre
http://allallan.blogspot.com/2008/04/nnvc-valuation.html

[Larry_1]

Antwort auf Beitrag Nr.: 37.089.506 von 1upandaway am 04.05.09 13:57:54

Danke für deine Meinung

[Larry_1]

guter Link

[Larry_1]

Schweinegrippe gerade wieder aktuell
Aktie wollte schon gestern wieder nach oben
und heute ?

[1upandaway]

NanoViricides, Inc. Anti-Herpes Drug Candidate Reduces Viral Load by 99.99%
http://finance.yahoo.com/news/NanoViricides-Inc-AntiHerpes-b…

Currently, there is no cure for herpes infection.

The market size for herpes simplex virus treatments is in excess of $2 billion annually.

[Larry_1]

Antwort auf Beitrag Nr.: 37.744.237 von 1upandaway am 10.08.09 13:25:11

http://www.azonano.com/news.asp?newsID=13058

endlich mal wieder die richtige Richtung

[1upandaway]

Antwort auf Beitrag Nr.: 37.748.625 von Larry_1 am 10.08.09 20:37:45

das ding bleibt die nächsten jahre in meinem depot (3-5 jahre)
masterplan kursziel 100 dollar
schau ma obs auch so kommt

[Larry_1]

Antwort auf Beitrag Nr.: 37.748.868 von 1upandaway am 10.08.09 21:09:43

100 dollar
haben die dementsprechendes in der Pipeline, kannst Du mal diesbezüglich ein paar Sätze schreiben. Mein Englisch ist miserabel ....

ich wär schon mit 5 zufrieden

good luck

[Larry_1]

Habe mir die Pipeline angeschaut. sieht vielversprechend aus

[1upandaway]

Antwort auf Beitrag Nr.: 37.752.516 von Larry_1 am 11.08.09 11:43:42

Seite 57
All Directors and Executive Officers as a Group 63 Mio. - 57.84%
http://www.nanoviricides.com/NNVC_10SB.pdf

ein blog den ich schon länger lese
http://allallan.blogspot.com/2008/04/nnvc-valuation.html

chart von 2005
http://www.pinksheets.com/pink/quote/quote.jsp?symbol=nnvc

[1upandaway]

Antwort auf Beitrag Nr.: 37.752.862 von 1upandaway am 11.08.09 12:21:59

http://www.speedtrade.com/index.php?option=com_content&view=…

[1upandaway]

nnvc in the news
http://www.2theadvocate.com/news/52955807.html

[Larry_1]

gestern kurz vor Handelsschluß schöner Kaufandrang
Bin gespannt, ob das nur eine einmalige Sache war.

[1upandaway]

NanoViricides Platform Enables Rapid Development of Robust Nanomedicines Against Influenza and HIV


He then explained that FluCide™, was found to be as much ten to twenty times (10X to 20X or 1,000% to 2,000%) superior to oseltamivir (Tamiflu®, Roche), in lethal influenza virus challenge administered to mice.


“Imagine the day when we will never have to develop vaccines against influenza,” he said, adding, “That’s what FluCide™ would achieve.”

http://finance.yahoo.com/news/NanoViricides-Platform-bw-4221…

[1upandaway]

50 schneidet 200 tage linie - bullisch

http://stockcharts.com/h-sc/ui?s=NNVC&p=D&yr=3&mn=0&dy=0&id=…

[1upandaway]

NEWS
NanoViricides, Inc. Signs a Master Service Agreement with Southern Research Institute for further Influenza and HIV Studies

http://finance.yahoo.com/news/NanoViricides-Inc-Signs-a-bw-1…

[1upandaway]

NanoViricides Secures $4.3M in Financing
http://finance.yahoo.com/news/NanoViricides-Secures-43M-in-b…

[Larry_1]

http://www.finanznachrichten.de/nachrichten-2009-10/15289642…

Jeder Abschnitt liest sich top!
Jetzt ist die Unsicherheit bzw. Angst weg und die Optimisten sind wieder an der Reihe

[Larry_1]

Mein Depot sieht seit Tagen richtig Sch.... aus
Da freut man sich hier umso mehr über die Trendumkehr

[sven641]

Theracour Pharma verkauft jede Woche so um die 50.000 Aktien.

Ok die haben laut Bericht per 28.02.2009 28 %

weiß jemand wieso die andauernd Aktien verkaufen ?

[1upandaway]

sven641
http://investorshub.advfn.com/boards/read_msg.aspx?message_i…

zusammenfassung von der Influenza conference
http://investorshub.advfn.com/boards/read_msg.aspx?message_i…

[Larry_1]

go,go,go up

[1upandaway]

6 Companies Ready to Change the World and Deliver Your Unending Wealth in 2010
By Patrick Cox | December 30, 2009
http://breakthroughtechnologyalert.agorafinancial.com/2009/1…

[Larry_1]

Antwort auf Beitrag Nr.: 38.677.910 von 1upandaway am 06.01.10 19:23:32

Meine Fresse

wer soll das alles lesen und dann auch noch verstehen?
Kannst du bitte ein paar Stichworte geben

[sven641]

Jetzt ist aber schön Zug drin...endlich

Neue Infos gibts aber nicht oder habe ich was verpasst ?

[Larry_1]

Läuft wie d Sau nach oben

[sven641]

Hab noch einen anderen wert. Mdrna,der ging auch ab heute

Biotech scheint in im Moment

[Larry_1]

...gut zu laufen

Recht dast Du

[Larry_1]

[1upandaway]

NNVC einfach liegen lassen
Target 2013 Kurs 100 usd

Third, as soon as you read this, go online and make sure you have at least 10,000 shares of NNVC. More is ok, fewer is not. Remember rule number one, we are here to make money? Well I lied. We are here to get rich, filthy rich. Those 10,000 shares of NNVC will be worth $1M by 2014. So even if nothing else you learn here works (but it will) you will be a millionaire by 2014.

http://allallan.blogspot.com/

[1upandaway]

Antwort auf Beitrag Nr.: 38.731.132 von 1upandaway am 13.01.10 21:23:42

wenns funktioniert ist 100 noch konservativ

wird zeit das dieses seitwärtsgeschiebe zuende geht
http://bigcharts.marketwatch.com/quickchart/quickchart.asp?s…

btw allan ist seit anfang 2005 dabei

[Larry_1]

Antwort auf Beitrag Nr.: 38.731.132 von 1upandaway am 13.01.10 21:23:42

Wie werde ich Millionär ??

----> einfach 10000 NNVC kaufen und 4 Jahre liegen lassen.

Hmm, sollte man direkt machen, und dann jede Nacht davon träumen

[Larry_1]

was rechtfertigt diese enormen Kursziele??
weiß das jemand?

[Larry_1]

aktuelle Pipeline

http://www.nanoviricides.com/pipeline.html

[Larry_1]

http://www.finanznachrichten.de/nachrichten-2010-01/15861962…


...Das Unternehmen hat jetzt vier kommerziell wichtige Medikamente in der Pipeline, wobei wir eine Gesamtgröße des Marktes von etwa 40 Milliarden Dollar.....

[Larry_1]

das gehandelte Volumen wird täglich größer!

[1upandaway]

NanoViricides Announces a Research Agreement With Leading Dengue Virus Researcher at the University of California, Berkeley
http://finance.yahoo.com/news/NanoViricides-Announces-a-bw-2…

[1upandaway]

aus dem i-hub board:
Agora Financial also mailed a reiteration today. Could this account for the afternoon run?

[...]This caution means that corporate press releases are often significantly understated. On the topic of vaccinations, the irony of The Lancet's repudiation is that vaccinations might well be obsolete in a very short time. NanoViricides (NNVC: OTCBB), as you know, seems poised to produce a nano/biotech product capable of killing viruses as soon as they are detected. Such a product could make many vaccinations unnecessary. Why, for instance, would you get a flu shot that may or may not be needed or work if you could simply wipe out the flu virus as soon as you were infected?

If you haven't yet added NanoViricides to your portfolio, I would read this press release
http://finance.yahoo.com/news/NanoViricides-Invited-to-bw-14…
If the statements in this story are true -- and I'm convinced they are -- this company is going to revolutionize the treatment of communicable disease. More importantly, it is currently entering into significant research arrangements with numerous prestigious organizations. When sufficient third-party validation is available for this amazing technology, we're going to see the company skyrocket

[1upandaway]

I sent a note out earlier today to my subscribers, suggesting a $4 target in the weeks ahead. The count on the chart below suggests a range of about $3.90 - $5.60 for this measured EW move.
http://allallan.blogspot.com/2010/03/nnvc-weekly-projections…

[sven641]

Hab nix dagegen wenn wir auf 5 gehen

[1upandaway]

mein ziel liegt im 3stelligen kursbereich
wenn die technologie funktioniert ....
mein zeithorizont die nächsten 5 jahre

[sven641]

Antwort auf Beitrag Nr.: 39.157.223 von 1upandaway am 17.03.10 11:46:40

wenn du so bullish bist, müßte man ja hier noch was schnappen.

Und wenns nicht funktioniert, wo ist der Kurs dann ?

[1upandaway]

Antwort auf Beitrag Nr.: 39.157.601 von sven641 am 17.03.10 12:19:31

[sven641]

hab nix dagegen

[1upandaway]

es erwartet uns eine spannende woche
Agora Financial - Patrick Cox's article will come out next week with a Glowing report on NNVC

[sven641]

Na dann kann ja nix schief gehen

dEr hat ja einen supertouch

hab die Aktien von dem alle im Depot

nnvc
isco
rxii
mrna

besser geht's nicht

[1upandaway]

Antwort auf Beitrag Nr.: 39.311.394 von 1upandaway am 11.04.10 21:24:09

Patrick Cox: Revolutionary Virus Research Expands NanoViricides' Potential Market Further

Part of the reason that I write about NanoViricides Inc. so frequently is that the company is at such an exciting point in its development. Specifically, the NanoViricides team has proven their revolutionary combination of nanotechnology and biotechnology works in animal studies. They've demonstrated that their nano-bio structures can fool human-infecting viruses in animal bloodstreams into harmlessly releasing their DNA.

They did this, as you may remember, in mouse lethality studies that proved their drug, FluCide, vastly superior to the current best flu treatment, Tamiflu. Mouse lethality studies require that no further treatments are given to test animals beyond the initial dosing. So the test mice were allowed to die, but blood work indicated that NanoViricides’ FluCide essentially “cured” the massively infected mice.

Beyond that, the company has made its technology available to important scientists at clearly prestigious institutions, including Department of Defense labs, for investigation and verification. They simply wouldn't have done this if they were not confident that the FluCide results would be replicated on other viruses. Among the tests that have been publicly announced are in vitro dengue virus, in vitro HIV, in vivo Ebola and in vivo rabies.

My fear is that once a number of positive test results are known, it will become obvious that NanoViricides is going to demolish the existing virus medication industry. At that point, the opportunity to own a piece of this transformation technology at bargain-basement prices will be gone.

So how big is that market? Estimates I've seen range from $20-29 billion annually and are growing. As far as I can tell today, NanoViricides will eventually dominate that industry. Even if other unexpected anti-virus technologies are discovered, the head start that the company has now assures that it will do very, very well for a long time.

I had expected, in fact, that we would be getting those results now. Instead, NanoViricides' “quiet period,” due to an S3 finance filing with the FDA, has extended longer than expected. This, I think, is a good thing. It gives you more time to examine the company and add it to your portfolio if you haven't already done so.

One more technical note on this topic: Investors often react negatively when a company brings in additional financing. If, however, this financing accelerates return on investment (ROI), dilution of equity may be counterbalanced by an increase in total present value. I think this is clearly the case with NanoViricides' current financing move, but it might provide some downward movement if you're looking to buy on dips.

So because NanoViricides executives can't talk about ongoing tests at the moment, I took the opportunity to ask CEO Dr. Eugene Seymour about a subject that has fascinated many scientists for the last few years. It is the newly discovered genetic connection between viruses and diseases that we have not traditionally viewed as virus diseases. In the last several weeks, in fact, several papers have been published bearing on this subject.

One, published in PLoS ONE, demonstrates that four HIV drugs also inhibit a retrovirus linked to prostate cancer and chronic fatigue syndrome. This story, about the study, in Science Daily, points out that, “The findings suggest that if XMRV (xenotropic murine leukemia virus-related virus) is proven to be a cause for prostate cancer or chronic fatigue syndrome, those illnesses may be treatable with drugs already approved for treating HIV.”

This is entirely plausible, as it is known that viruses have the ability to impair the host's immune system. This is a simple self-defense function on the part of viruses, but its implications are profound both for medical researchers and investors. Not only is prostate cancer linked to specific viruses, leukemia and other cancers seem to be triggered or driven by viruses.

An article in Medical News Today discusses work done by French researchers in the Retrovirus Endogenes et Elements Retroides des Eucaryotes Superieurs Laboratory. The most important part of this story is in the last paragraph: “The researchers succeeded in locating the domain responsible for this property within the amino acid sequence of the envelope protein. This domain, an authentic virulence factor, is a crucial element in the arsenal that enables retroviruses to invade their host and produce their pathogenic effect. It thus becomes a target of choice for the design of novel antiretroviral therapeutic strategies, including vaccines.”

This is, in fact, what NanoViricides' nanotech structures do. Moreover, the scientist behind NanoViricides' platform, Anil R. Diwan, Ph.D., has an 18-year head start on those who have just figured this out. The implication, now, is that this approach could have far greater application than treating infections by viruses.

For example, a researcher in Glasgow has found that childhood diabetes is associated with the presence of a particular virus. This discovery has been made just as Cambridge University researchers have published a study in the journal Science showing that type 1 diabetes is linked to mutations in a gene involved in the immune response to enteroviruses.

So scientists who wrote the PLoS ONE article are pondering the possibility of treating or preventing prostate cancer and chronic fatigue syndrome with existing HIV drugs. Obviously, NanoViricides' superior therapy would have any greater potential. Similarly, the possibility exists that NanoViricides will have therapies for childhood diabetes as well as other diseases that many scientists believe to be mediated by viruses. This includes, incidentally, obesity and even some mental disorders. As the genome continues to be unraveled, I predict that we will find many other diseases have virus triggers.

There has been speculation to this effect for decades. What is revolutionary is the new tools that scientists are bringing to this research arena. The decoding of the human genome is one of the most important… and one of the most startling.

Listen, for example, to Dr. Phillip A. Sharp of the Center for Cancer Research at MIT. His Nobel Prize is in recognition for his role decoding the genome. He says that “We humans are well over 50% viral.”

That's right. Sharp says that half or our DNA has come from viruses. We're speaking about the so-called “junk DNA” that was initially assumed to have no active role. Today, this belief is being jettisoned. Some researchers, such as Luis P. Villarreal, director of the Center for Virus Research at the University of California, Irvine, believe humans have benefited from DNA viruses in yet unknown ways. (If you're interested in the subject you can find more here and here.)

I realize that this may be seem a bit much to process if the subject is new to you. So I asked NanoViricides CEO Dr. Eugene Seymour to comment on this emerging science and what it means to his company. Following is what he wrote.

Dr. Eugene Seymour Comments
“It's now quite obvious that many of the medical profession's most cherished notions are now being overturned by virtue of new research. My friend Dr. Howard Lipton has maintained that the initiating cascade for MS starts with a viral infection. Dr. Lipton is professor of immunology and neurology at the University of Illinois College of Medicine and previously was chairman of the Neurology Department at the Mount Sinai School of Medicine. One of his former colleagues, an oncologist at that medical school, feels that the initiating cascade for breast cancer comes from a retrovirus, the mouse mammary virus.

“It's interesting to note that XMRV is also a retrovirus. I feel that the intense research interest in HIV/AIDS will lead to further understanding of the links between cancer, the immune system and viruses. The number of virus-associated cancers now stands at eight, but I firmly believe that by the end of this decade, that number will at least quadruple.

“This work started with Dr. Francis Peyton Rous in 1911. The Rous sarcoma virus is named after him. I interviewed him in 1961, 50 years after his groundbreaking discovery that a virus could cause a malignancy. He was almost laughed out of the medical profession. He was awarded the Nobel Prize in Medicine 55 years later for that discovery. This was before the true nature of viruses had been discovered. So little work has been done on interrupting the linkage between a virus infection and the subsequent development of a malignancy. In 1997, Dr. Lawrence Altman, a physician-journalist from The New York Times, wrote, ‘An emerging theory is that most AIDS-related cancers are somehow linked to viral infections. But doctors do not know if HIV enhances the ability of other viruses to produce certain cancers.’

“Since there has never been a nontoxic way to destroy viruses (before the advent of nanoviricides), uncoupling the link has been a difficult task.

“Of the eight verified cancers caused by viruses, I've seen almost all of them... some in the U.S. and some in my travels worldwide. My son, when he was a resident at UCSF, saw a Chinese male with nasopharyngeal carcinoma (ultimately fatal) that was caused by a prior Epstein-Barr infection. I saw a number of these cases in China when I went there to teach the Chinese doctors how to use my AIDS test.

“I'll never forget a patient I had as a medical student on the surgical service. He was a 30-year-old who was an oil field worker in Nigeria. He presented to us with a widely metastatic carcinoma and a strange immune system collapse that we had never before seen. He died of massive overwhelming septicemia. Even though this was in the mid-1960s, 15 years before the first AIDS cases were reported, I feel that he was, in reality, the first AIDS patient I ever saw!

“I like to go back to the story of Dr. Barry Marshall, who completely upset the medical establishment with his suggestion that peptic ulcers were caused by a bacteria. He drank a brew of bacteria and managed to cause a rip-roaring gastroenteritis, which he quickly eradicated with antibiotics. Thus, almost overnight, the long-standing treatment paradigm (often surgical) was overturned.

“So how does NanoViricides Inc. fit into this picture? I'll just focus on herpesviruses and retroviruses for the purpose of this discussion. Epstein-Barr virus is a herpesvirus. We've already tested our nanoviricides against herpesviruses and have reported excellent results! With respect to retroviruses, we've done the same with HIV, which is itself a retrovirus. I feel that as we move forward with additional animal and human studies, others will take the appropriate nanoviricides and use them to evaluate the links to various cancers. I also feel that 100 years after Dr Rous' discovery, we too are poised to make a significant contribution to both the understanding and potential eradication of virus-caused malignancies.

“This is a complex undertaking and is outside the scope of our present R&D plans. Others will have to take our drugs and assume the responsibility of investigating the virus-cancer links. If these researchers can confirm the links and impact the status of a malignancy with treatment with our optimized nanoviricides, then the paradigm for treatment of cancers will have been inexorably altered.

“Incidentally, I have no interest in infecting myself with one of these viruses to see if a malignancy is the outcome. Any volunteers?”
Uh, I doubt it, Dr. Seymour.

But I am enormously excited about the possibility that nanoviricides could play a much larger role in disease prevention and treatment than is currently projected. We'll be following this area closely as it unfolds.

For transformation profits,

Patrick Cox

P.S. Now, more than ever, is a great time to make sure you don’t miss a single Breakthrough Technology Alert. For a special offer on extending your subscription take a look below...
Special Offer: Act today to Save $400 off Another Year of Breakthrough Technology Alert




Nothing in this e-mail should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice.


We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.


©

[sven641]

Sieht gut aus mit neuem financing.Da hatten wohl einige auf shorts gesetzt die letzten Tage

[sven641]

Offensichtlich gab es einige News,die sich laut Yahoo-Forum in USA
positiv auf den Kurs auswirken sollten

[sven641]

Was sagt Ihr zu den Zahlen von heute ?


Weitere Ausblick ?


Aktie kam ja am Freitag ganz gut zurück.

[1upandaway]

In 25 years of research, I’ve never seen anything like this revelation of profits…

It’s not out of the question to say that this could be the biggest wealth explosion in history.

And I’m not kidding when I say this is the biggest story you’ll see this year…or for the next 10 years.

By Patrick Cox | May 24, 2010 |
http://breakthroughtechnologyalert.agorafinancial.com/2010/0…

[1upandaway]

Posted by Dave Banister on May 28th, 2010 at 11:34 AM

NNVC- This is a speculative biotech-nanomedicine company with a laboratory and offices near Yale University in West Haven, CT. I visited in person on May 27th taking a 2 hour drive there from my office in Rhode Island. I spent about 2 hours with the team and below is my summary:

Present were Dr. Anil Diwan, CEO and Co-Founder of NNVC. Dr. Randall Barton, Chief Scientific Officer, and Dr. Jay Tatake, Head of Chemistry.

This group of men has an astoundingly strong background both academically and professionally. Jay and Randy both have extensive experience working for and with Big Pharma. Dr. Diwan is a brilliant scientist who has extensive research and development work to his credit going back to 1991. From 1991-1999 he was working under a research grant at a large science park near Yale University. He worked on top secret development of Drug agents for major pharmaceuticals. He has also studied and taught at Rice University, as well as completed studies and research of particle mapping and blood clotting research at The University of Wisconsin-Madison. This is where he was the first ever to use nanomicelles.

The fledgling young company was founded in 2005 officially as Dr. Diwan was introduced to Dr. Eugene Seymour in 2003 and one thing led to another. As Dr. Seymour finished up contract work for a larger pharmaceutical firm that was being sold to Teva, he was then free to join with Dr. Diwan to begin this venture. The decision was made to list the company publicly so as to best raise funds rather than staying private. To wit, they are currently working on paperwork and filing requirements for an up-listing to the AMEX exchange, which would certainly help with credibility and potentially additional larger shareholders and with raising future funds.

Per Dr. Barton, the company has had good success at “in vivo and in vitro” analysis and results, and they now need to focus on one main area to take to the FDA level for pre-IND initiation discussions. The newer Nano technology is a learning curve for the FDA, so it will take some time to educate the FDA, get feedback, get buy-in from them, and then proceed forward with further pre-clinical work and later trials. The easiest path to accomplish this will be using the path of least resistance. This may be Dengue Fever, or perhaps Herpes.

NNVC is testing 8 different areas for Viral Therapeutics, with the highlights currently being Dengue Fever, Ebola, HIV, Herpes, and Rabies. I toured the new laboratory facilities which are really clean and filled with brand new high end equipment. The company currently has 10 employees total and is looking to staff up to help with the juggling of 8 balls at various stages of scientific work. There were many brand new pieces of equipment still in boxes and being unwrapped and set up in various rooms. They have also taken additional space for more expansion and future production as they get into phase 1 trials down the road and hire more staff.

Data is currently coming in on Dengue Fever work, and is being cross checked and verified before results are released. This is the second set of studies, following the in vitro (petrie dish) type work, the In Vivo (Animal) studies are the ones I assume are being put together now (Mice). HIV “in vitro” results have come in and are also being cross checked and likely soon released. Ebola study findings will be shared in July at a major biological societal meeting using NNVC’s nanotechnology. Results can take awhile to process and then release due to negative control procedures, double blind studies on each end, and the layers of Project managers, lab staff, institutions, and attorney’s that must all sign off together before data can be released.

If the company was to layout the areas of the most interest and excitement for them in the next few years it would be roughly as follows:

1. HIV is the most exciting, but also has something like 20 different strains and can reside in the Human Body for a lengthy period of time. This makes trials very long and expensive; however the early results appear to be quite encouraging.

2. EKC- Herpes- NNVC is trying to work on how to best block the sleeping cells and have made strong progress.

3. Dengue Fever- There is no known therapeutic for it now, and Dr. Diwan estimates it at a 2 billion current market. A recent flare-up in Florida only highlights the problem. Unlike HIV where there are products and multiple trials ongoing, NNVC arguably is the first company to attack Dengue Fever in the laboratory and with studies. This is an area of potential first mover advantage for NNVC.

4. Rabies- Rabies is extremely difficult to attack. The NNVC team calls it “Nobel prize winning” type of work, which could take many years of study and still never be solved. However, it is an area of focus.

5. Influenza- The theory here is they could attack the strains each season and come up with solutions within a very short period of time.

Some other notes are that there are no currently issued patents, but they are pending. Also, the company takes the highest levels of care and safety in guarding their secret methodologies and formula’s as it were. The exciting part about the Nanomicelle being developed as the therapeutic agent or virus killer is the toxicity is not present. It would release through the body’s normal excretion paths much like absorbing and digesting food.

There is a long road ahead for NNVC and they have 4 trials ongoing now at various labs/institutions. We hope to see some HIV and Dengue results, along with Ebola in the next 60 days time window, and perhaps an AMEX listing. These could all be catalysts to move the shares higher.

The stock is speculative and should not be over weighted as I’ve mentioned before. I will continue to follow the story closely and monitor the technical action. I came away impressed with the buttoned down scientific attitude of the team. They were all very down to earth and enjoy the work they are doing, and also realize it is a long road. Dr. Diwan is extremely proud of his work and very excited by the potential for Nano Therapeutics using the Nanomicelle being developed as agents. In summary, I wanted to get a feel for the people and the scientific backgrounds, and the processes in place. Like many biotech firms, this is a heavy research and development stage based company and they will succeed or fail based on results from studies, financings, and sponsors/supporters. So far at an early stage, NNVC seems to be on a strong path.
David A. Banister
Chief Investment Strategist

www.ActiveTradingPartners.com
www.TheMarketTrendForecast.com

Active Trading Partners, LLC

[sven641]

Hört sich doch gut an.

Ich hoffe,dass die Biotechs mal wieder mit dem Markt nach oben gehen.

[sven641]

Neue Ideen zu NNVC ?

[sven641]

Jetzt ist ja ganz schön Zug drin bei der Aktie....

[1upandaway]

Patrick Cox, Breakthrough Technology Alert, on NanoViricides

August 17, 2010

NanoViricides' Nano-Juggernauts Annihilate Another Barrier to Blockbuster Status

Dear Breakthrough Technology Reader,

NanoViricides Inc. (NNVC: OTCBB) continues to prove that its core science is exactly what company scientists say it is. Yesterday, the company announced third-party validation of several anti-herpes drug candidates. The cell culture studies were performed by leading herpes scientist Dr. Ken Rosenthal, at Northeastern Ohio Universities Colleges of Medicine and Pharmacy.

The study "demonstrated significant efficacy," according the announcement. This is, as you know, exactly what I've been predicting.

Moreover, the Rosenthal test results were actually more significant than the language of the press release might lead to you to assume. The release stated:
"Several of the anti-herpes nanoviricides demonstrated a dose-dependent maximal inhibition of herpes virus infectivity in a cell culture model. Almost complete inhibition of the virus production was observed at clinically usable concentrations. These studies employed the H129 strain of herpes simplex virus type 1 (HSV-1). H129 is an encephalitic strain that closely resembles a clinical isolate; it is known to be more virulent than classic HSV-1 laboratory strains. The H129 strain will be used in subsequent animal testing of nanoviricides."
Saying that H129 is "more virulent" than other strains of herpes is a nice example of scientific understatement. This especially nasty form of the virus is particularly hard to treat. Typically, it attacks the brains of children. If not properly diagnosed and treated, 70% of the victims die. Treated, 20% die. Among survivors, more than half suffer permanent brain damage. H129 is herpes from hell.

Obviously, a less hardy herpes serotype could have been used in these in vitro cell studies. It would have been warranted, in fact, because the market for a topical herpes drug will be mostly in treating genital herpes and cold sores. The fact that the bar was so high in this study is an indication of the confidence that both Rosenthal and the NanoViricides crew have in their nanotech virus killer.

The newly announced results prove their confidence was warranted. We now know that the NanoViricides technology kills the herpes bug dead in cell culture. The cell culture studies, however, exposed the virus directly to the bio/nanotech structures. For a topical to work in real life, the nanoviricides will have to penetrate a herpes vesicle or blister.

Next on the road map to herpes drug blockbuster status, therefore, are animal studies. In these studies, Rosenthal et al. will probably apply an ointment or lotion containing the most effective of the nanoviricides to animals with herpes vesicles. This will determine whether or not nanoviricides can penetrate the visible herpes sore and kill the virus. If they do, we are looking at a topical treatment worth billions of dollars annually on the relatively near horizon. Remember, 25% of adult Americans have genital herpes.

If the nanoviricides topical does not readily penetrate the herpes blister, researchers will begin investigating the many well-established techniques for increasing the permeability of cellular barriers. I have no doubt that a solution will be found. This could slow down the process of developing and licensing a topical herpes medication, but it wouldn't stop it. Nor would this worst-case scenario negate the potential of NanoViricides' blockbuster platform.

So how soon will we know if Rosenthal's topical treatment needs additional tweaking? Fortunately, we're dealing with viruses, not cancers. Viruses are a life-form with a very short life span. Theoretically, Rosenthal could move immediately into animal tests. If he does, results could be available in a matter of weeks. It would take somewhat longer to analyze and publish the results, but we're not looking at years. We’re not looking at even a single year.

Personally, my guess is that the nanoviricides will, in fact, penetrate herpes vesicles. This is based simply on what I know about the size of the nanoviricide structure, which is smaller than many other molecules that easily pass through similar membranes.

While the market for a topical herpes medicine is enormous, it is only the first step in NanoViricides' plan to completely eradicate the virus. Step two is to develop the technology necessary to get their nano/biotech structures into the nerve ganglions where herpes hides.

There have, in fact, been some published indications that lead us to believe this is possible. This is exciting for a number of reasons. One is that it means that it may be able to use the same ability to destroy the HIV virus where it hides. For the first time, it would be possible to "cure" rather than "treat" AIDS.

One more thing; Sens. Sam Brownback and Al Franken have introduced bipartisan legislation that would add rare childhood diseases to the list of conditions that are eligible for priority review vouchers. I haven't seen a list or full description of the diseases, but there are many rare virus-caused childhood diseases. It appears that this legislation, if it becomes law, will increase the potential for NanoViricides to profit from this amazing program.

Priority review vouchers (PRVs), as I've explained, are "golden tickets" that allow pharmaceutical companies to jump to the head of the FDA line. This ability is worth, conservatively, hundreds of millions of dollars. More importantly, these chits can be sold to Big Pharma. As I've told you before, one Big Pharma executive told me that an internal study from one of the biggest pharma coms valued the chits at about $380 million. NanoViricides is already on track to winning a dengue PRV.

Obviously, I am enormously excited about the upcoming animal studies and will try to get you more information soon. Personally, I haven't been as excited about a looming event since the U.S. soccer team qualified for the second round of the last World Cup.

[Larry_1]

mal schaun was geht

[sven641]

Heute sieht es endlich mal wieder gut aus..........

[Rexx1]

Daten vom heutigen Börsen-Tag:

Börsenplatz: NASDAQ OTC BB
Schlussnotiz: 1,31 US-Dollar (+ 23,58%)
Tageshoch / -tief 1,33 1,0675
Umsatz-Volumen: 2,092 Mio. Stück

[Larry_1]

Bin hier heute wieder mal eingestiegen
Man will ja schließlich nichts versäumen

[sven641]

[/thread]Na dann push das Ding mal hoch

[sven641]

läuft weiter ohne News

vielleicht knachen wir noch die 2 USD dieses Jahr

[Larry_1]

Antwort auf Beitrag Nr.: 40.504.957 von sven641 am 11.11.10 18:48:20

dieses Jahr ??
wenn die so weiterläuft, dann sind wir bereits nächste Woche schon bei 2 Dollar,
jeden Tag schließt die fast auf Th, dies ist ein gutes Zeichen

[Larry_1]

Antwort auf Beitrag Nr.: 40.505.721 von Larry_1 am 11.11.10 20:12:32

deshalb gehts up:

http://www.finanznachrichten.de/nachrichten-2010-11/18407021…

[sven641]

das ist aber schon eine Woche her........

[Larry_1]

Antwort auf Beitrag Nr.: 40.508.132 von sven641 am 12.11.10 08:56:48

genau, da begann doch auch der Anstieg, oder???

[sven641]

das stimmt,aber das war meiner Ansicht nach gut für den Move von 1,03 auf 1,25-1,30 bis zum 5.11.

der letzte Push muss was anderes sein oder einige shorts mußten eindecken....

anyway ich hoffe wir machen so weiter

Schönes Wochenende

[Larry_1]

Antwort auf Beitrag Nr.: 40.508.809 von sven641 am 12.11.10 09:56:14

ist mir eigentlich auch egal, was der Grund ist, Hauptsache es geht mal nachhaltig up

auch ein schönes WE

[sven641]

sieht sehr gut aus

[Larry_1]

Antwort auf Beitrag Nr.: 40.536.191 von sven641 am 17.11.10 10:28:31

ich überlege schon ein paar Tage, ob ich hier nochmal nachkaufen sollte..

[sven641]

Ich hab so viel, ich kaufe nichts mehr, bin einfach froh über die Kursentwicklung.

Man sieht aber die letzten Tage bei der allgemeinen Kursschwäche, dass der Kurs anzieht.

Das ist auch bei den anderen Biotechs die ich habe so.

BTX und ISCO


Es gibt einige die glauben, dass wenn Nano erfolgreich wird, dass der Kurs Potential bis 50 USD oder höher hat.

Das wäre dann der vorzeitige Rententrade.

Wir werden sehen.........

[Larry_1]

Antwort auf Beitrag Nr.: 40.545.524 von sven641 am 18.11.10 13:09:34

BTX und ISCO

oh,oh, was sind das denn für exotische Aktien?? Wie lautet denn die WKN der beiden?